語系:
繁體中文
English
說明(常見問題)
回圖書館首頁
手機版館藏查詢
登入
回首頁
到查詢結果
[ subject:"Oncology." ]
切換:
標籤
|
MARC模式
|
ISBD
MicroRNA and Energy Metabolism in Ga...
~
Huang, Wen-Kuan.
FindBook
Google Book
Amazon
博客來
MicroRNA and Energy Metabolism in Gastrointestinal Tumors.
紀錄類型:
書目-電子資源 : Monograph/item
正題名/作者:
MicroRNA and Energy Metabolism in Gastrointestinal Tumors./
作者:
Huang, Wen-Kuan.
出版者:
Ann Arbor : ProQuest Dissertations & Theses, : 2020,
面頁冊數:
67 p.
附註:
Source: Dissertations Abstracts International, Volume: 82-09, Section: B.
Contained By:
Dissertations Abstracts International82-09B.
標題:
Oncology. -
電子資源:
https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28420859
ISBN:
9798582536499
MicroRNA and Energy Metabolism in Gastrointestinal Tumors.
Huang, Wen-Kuan.
MicroRNA and Energy Metabolism in Gastrointestinal Tumors.
- Ann Arbor : ProQuest Dissertations & Theses, 2020 - 67 p.
Source: Dissertations Abstracts International, Volume: 82-09, Section: B.
Thesis (Ph.D.)--Karolinska Institutet (Sweden), 2020.
This item must not be sold to any third party vendors.
MicroRNAs (miRNAs) contribute to cancer development and drug resistance via cellular biological processes, including metabolic pathways. Energy metabolism plays a significant role to maintain tumor proliferation in gastrointestinal (GI) cancers. However, the roles of miRNAs and energy metabolism in GI cancers are not fully understood. The studies presented in this thesis aim to provide further insights into the biological role of miRNAs, energy metabolism, and the interplay between miRNAs and energy metabolism in GI cancers, using gastrointestinal stromal tumor (GIST) and colon cancer as the models.In Paper I, we explored the downstream target of miR-125a-5p-PTPN18 axis that contributes to imatinib resistance in GIST. We found that over-expression of miR-125a-5p and silencing of PTPN18 increased phosphorylated focal adhesion kinase (pFAK). FAK inhibitor 14, which blocks phosphorylation of Y397-FAK, enhances imatinib response in imatinib-resistant GIST cells. Furthermore, FAK inhibitor 14 could rescue the imatinib resistance mediated by overexpression of miR-125a-5p, suggesting that pFAK is the downstream target of the miR-125a-5p-PTPN18 axis.In Paper II, we profiled the bioenergetic phenotype of imatinib-resistant GIST cells. We identified two major types of bioenergetics in imatinib-resistant GIST cell lines and clinical samples, i.e. highly metabolically active phenotype with higher glycolysis and oxidative phosphorylation (OXPHOS) andlow OXPHOS types. Metabolic inhibitor assays revealed that imatinib-resistant GIST 882R cells (with highly metabolically active phenotype) were more sensitive to glycolysis inhibition than the parental GIST 882 cells, while imatinib-resistant GIST T1R cells (with low OXPHOS) were more resistant to OXPHOS inhibition than GIST T1. Our study demonstrates metabolic heterogeneity and diverse vulnerability of GIST cells to metabolic inhibitors, suggesting the potential of targeting energy metabolism for overcoming imatinib resistance in GIST.In Paper III, we further explored the relationship between miRNA and imatinib treatment in GISTand the effect on OXPHOS. Using microarray and RT-qPCR, we identified miR-483-3p as one of the most down regulated miRNAs in imatinib-treated GISTs. Imatinib treatment resulted in downregulation of miR-483-3p and upregulation of OXPHOS in imatinib sensitive GIST cells.Modulation of miR-483-3p altered protein expression of mitochondrial respiratory Complex II,suggesting its involvement in OXPHOS regulation. This study reveals a potential role of miR-483-3p in imatinib-induced OXPHOS expression.In Paper IV, we investigated the association of metformin treatment, an inhibitor of OXPHOS, with patient survival in colorectal cancer. We showed that metformin users were associated with 44% lower risk of mortality compared with nonusers. These findings suggest that metformin could be an adjunct to standard treatment of colorectal cancer.Overall, this thesis work provides new insights into the role of miRNAs and energy metabolism in drug response and potential clinical use in GI cancers.
ISBN: 9798582536499Subjects--Topical Terms:
751006
Oncology.
Subjects--Index Terms:
MicroRNAs
MicroRNA and Energy Metabolism in Gastrointestinal Tumors.
LDR
:04251nmm a2200337 4500
001
2279304
005
20210730131636.5
008
220723s2020 ||||||||||||||||| ||eng d
020
$a
9798582536499
035
$a
(MiAaPQ)AAI28420859
035
$a
(MiAaPQ)Karolinska_1061647326
035
$a
AAI28420859
040
$a
MiAaPQ
$c
MiAaPQ
100
1
$a
Huang, Wen-Kuan.
$3
3557747
245
1 0
$a
MicroRNA and Energy Metabolism in Gastrointestinal Tumors.
260
1
$a
Ann Arbor :
$b
ProQuest Dissertations & Theses,
$c
2020
300
$a
67 p.
500
$a
Source: Dissertations Abstracts International, Volume: 82-09, Section: B.
500
$a
Advisor: Lui, Weng-Onn;Branstrom, Robert;Larsson, Catharina;Caramuta, Stefano;Hansson, Johan.
502
$a
Thesis (Ph.D.)--Karolinska Institutet (Sweden), 2020.
506
$a
This item must not be sold to any third party vendors.
520
$a
MicroRNAs (miRNAs) contribute to cancer development and drug resistance via cellular biological processes, including metabolic pathways. Energy metabolism plays a significant role to maintain tumor proliferation in gastrointestinal (GI) cancers. However, the roles of miRNAs and energy metabolism in GI cancers are not fully understood. The studies presented in this thesis aim to provide further insights into the biological role of miRNAs, energy metabolism, and the interplay between miRNAs and energy metabolism in GI cancers, using gastrointestinal stromal tumor (GIST) and colon cancer as the models.In Paper I, we explored the downstream target of miR-125a-5p-PTPN18 axis that contributes to imatinib resistance in GIST. We found that over-expression of miR-125a-5p and silencing of PTPN18 increased phosphorylated focal adhesion kinase (pFAK). FAK inhibitor 14, which blocks phosphorylation of Y397-FAK, enhances imatinib response in imatinib-resistant GIST cells. Furthermore, FAK inhibitor 14 could rescue the imatinib resistance mediated by overexpression of miR-125a-5p, suggesting that pFAK is the downstream target of the miR-125a-5p-PTPN18 axis.In Paper II, we profiled the bioenergetic phenotype of imatinib-resistant GIST cells. We identified two major types of bioenergetics in imatinib-resistant GIST cell lines and clinical samples, i.e. highly metabolically active phenotype with higher glycolysis and oxidative phosphorylation (OXPHOS) andlow OXPHOS types. Metabolic inhibitor assays revealed that imatinib-resistant GIST 882R cells (with highly metabolically active phenotype) were more sensitive to glycolysis inhibition than the parental GIST 882 cells, while imatinib-resistant GIST T1R cells (with low OXPHOS) were more resistant to OXPHOS inhibition than GIST T1. Our study demonstrates metabolic heterogeneity and diverse vulnerability of GIST cells to metabolic inhibitors, suggesting the potential of targeting energy metabolism for overcoming imatinib resistance in GIST.In Paper III, we further explored the relationship between miRNA and imatinib treatment in GISTand the effect on OXPHOS. Using microarray and RT-qPCR, we identified miR-483-3p as one of the most down regulated miRNAs in imatinib-treated GISTs. Imatinib treatment resulted in downregulation of miR-483-3p and upregulation of OXPHOS in imatinib sensitive GIST cells.Modulation of miR-483-3p altered protein expression of mitochondrial respiratory Complex II,suggesting its involvement in OXPHOS regulation. This study reveals a potential role of miR-483-3p in imatinib-induced OXPHOS expression.In Paper IV, we investigated the association of metformin treatment, an inhibitor of OXPHOS, with patient survival in colorectal cancer. We showed that metformin users were associated with 44% lower risk of mortality compared with nonusers. These findings suggest that metformin could be an adjunct to standard treatment of colorectal cancer.Overall, this thesis work provides new insights into the role of miRNAs and energy metabolism in drug response and potential clinical use in GI cancers.
590
$a
School code: 0658.
650
4
$a
Oncology.
$3
751006
653
$a
MicroRNAs
653
$a
Energy metabolism
653
$a
Gastrointestinal cancers
690
$a
0992
710
2
$a
Karolinska Institutet (Sweden).
$3
3557748
773
0
$t
Dissertations Abstracts International
$g
82-09B.
790
$a
0658
791
$a
Ph.D.
792
$a
2020
793
$a
English
856
4 0
$u
https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28420859
筆 0 讀者評論
館藏地:
全部
電子資源
出版年:
卷號:
館藏
1 筆 • 頁數 1 •
1
條碼號
典藏地名稱
館藏流通類別
資料類型
索書號
使用類型
借閱狀態
預約狀態
備註欄
附件
W9431037
電子資源
11.線上閱覽_V
電子書
EB
一般使用(Normal)
在架
0
1 筆 • 頁數 1 •
1
多媒體
評論
新增評論
分享你的心得
Export
取書館
處理中
...
變更密碼
登入